Skip to content
Study details
Enrolling now

Trial of Suvorexant for Sleep in Children With Autism

Stanford University
NCT IDNCT05546554ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

26

Study length

about 4.6 years

Ages

13–17

Locations

1 site in CA

About this study

Researchers are testing whether suvorexant helps children with autism sleep better. The trial will compare suvorexant to a placebo, using tests like polysomnography and actigraphy to measure sleep patterns. It will last 1664 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo
  • 2.Take Suvorexant
PhasePhase 2
DrugSuvorexant
Routeoral
Primary goalChange from baseline in sleep architecture as measured by polysomnography (PSG) and/or actigraphy, examples include sleep latency and non-rapid eye movement (NREM)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

suvorexant

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change from baseline in sleep architecture as measured by polysomnography (PSG) and/or actigraphy, examples include sleep latency and non-rapid eye movement (NREM)

Secondary: Change from baseline in sleep efficiency as measured by actigraphy

Body systems

Psychiatry / Mental Health